Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Apatinib Mesylate Tablets Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR Wild-type, Non-squamous, Non-small-cell Lung Cancer

NCT02852798 is registered in ClinicalTrials.gov with Jiangsu ShengDiYa Medicine Co., Ltd. as lead sponsor.

NCT NCT02852798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02852798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Apatinib Mesylate Tablets Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR Wild-type, Non-squamous, Non-small-cell Lung Cancer
Lead sponsor
Jiangsu ShengDiYa Medicine Co., Ltd.
Phase
Observational
Overall status
Unknown status
Start date
August 31, 2016
Completion date
August 31, 2018
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nonsquamous nonsmall cell neoplasm of lung